Cancer Research Technology
Log in Register
Menu

Anti-SIGLEC5 [1A5]

Invented by Prof Paul Crocker at University of Dundee

Info

Catalogue Number 151589
Applications ELISA FACS IHC IF IP Fn WB
Antigen/Gene or Protein Targets Siglec5
Synonyms Sialic Acid Binding Ig Like Lectin 5; Obesity-Binding Protein 2; OB-Binding Protein 2; CD33 Antigen-Like 2; SIGLEC-5; CD33L2; OBBP2; Sialic Acid-Binding Immunoglobulin-Like Lectin 5; CD170 Antigen;
Reactivity Human
Relevance The Siglecs are a family of membrane bound lectins (of the immunoglobulin superfamily) that bind sialic acid and mediate cell-cell interactions. Siglec5 (CD170) is a member of the recently-described human CD33-related siglec subgroup of sialic acid binding Ig-like lectins and is expressed on myeloid cells of the hemopoietic system. Similar to other CD33- related siglecs, Siglec-5 contains two tyrosine based motifs in its cytoplasmic tails implicated in signalling functions. The antibody cross reacts with Siglec14.
Host Mouse
Immunogen Siglec-5-Fc protein, containing entire extracellular region of siglec-5 fused with the Fc region of human IgG1
Positive Control Siglec5 transfected CHO cells. Apart from Siglec14 (Angata T et al. 2006 FASEB J. 20:1964-73. PMID: 17012248), non-cross-reactive with panel of other Siglec proteins, either expressed on CHO cells or as recombinant proteins.
Subclass IgG1
Myeloma Used Sp2/0-Ag14
Recommended Growing Conditions DMEM + 10% FetalClone I + 1% penicillin/streptomycin
Notes Recommended dilution for FACS: Cells (1x10^6) should be incubated with 1ug of antibody/100 ul in 1% BSA in PBS for 30–60 min on ice (Nguyen et al., 2006).
Research Area Adhesion, Cell Type or Organelle Marker, Immunology

References

There are 11 reference entries for this reagent.

View All References

References: 11 entries

Angata et al. 2006. FASEB J. 20(12):1964-73. PMID: 17012248.

Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates.

Europe PMC ID: 17012248

Nguyen et al. 2006. Proc Natl Acad Sci U S A. 103(20):7765-70. PMID: 16682635.

Nguyen et al. 2006. Proc Natl Acad Sci U S A. 103(20):7765-70. PMID: 16682635.

FACS

Loss of Siglec expression on T lymphocytes during human evolution.

Europe PMC ID: 16682635

Avril et al. 2005. J Biol Chem. 280(20):19843-51. PMID: 15769739.

Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.

Europe PMC ID: 15769739

Connolly et al. 2002. Br J Haematol. 119(1):221-38. PMID: 12358929.

IHC

Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions.

Europe PMC ID: 12358929

Cornish et al. 1998. Blood. 92(6):2123-32. PMID: 9731071.

Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33.

Europe PMC ID: 9731071


Add a reference

References: 11 entries

Angata et al. 2006. FASEB J. 20(12):1964-73. PMID: 17012248.

Discovery of Siglec-14, a novel sialic acid receptor undergoing concerted evolution with Siglec-5 in primates.

Nguyen et al. 2006. Proc Natl Acad Sci U S A. 103(20):7765-70. PMID: 16682635.

Nguyen et al. 2006. Proc Natl Acad Sci U S A. 103(20):7765-70. PMID: 16682635.

FACS

Loss of Siglec expression on T lymphocytes during human evolution.

Avril et al. 2005. J Biol Chem. 280(20):19843-51. PMID: 15769739.

Siglec-5 (CD170) can mediate inhibitory signaling in the absence of immunoreceptor tyrosine-based inhibitory motif phosphorylation.

Connolly et al. 2002. Br J Haematol. 119(1):221-38. PMID: 12358929.

IHC

Human Siglec-5: tissue distribution, novel isoforms and domain specificities for sialic acid-dependent ligand interactions.

Cornish et al. 1998. Blood. 92(6):2123-32. PMID: 9731071.

Characterization of siglec-5, a novel glycoprotein expressed on myeloid cells related to CD33.


Add a reference